AbbVie sees negative Q2, full-year impact from IPR&D and milestones expense

3 days ago 2

• Healthcare

hapabapa/iStock Editorial via Getty Images

• AbbVie (NYSE:ABBV) said it will incur a negative impact of $0.42 to GAAP and non-GAAP diluted earnings per share in Q2 due to acquired IPR&D and milestones expense of $823M.
• As a result, the company now sees Q2 adjusted diluted earnings

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. AbbVie sees negative Q2, full-year impact from IPR&D and milestones expense